Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer?

Abstract Background Lung cancer is the leading cause of cancer-related deaths worldwide. Therefore, the search for new biomarkers continues in order to diagnose lung cancer at an early stage. In this study, we investigated blood levels of G-protein associated membrane estrogen receptor (GPER)-1 and...

Full description

Saved in:
Bibliographic Details
Main Authors: Aykut Eliçora, Berrak Güven, Hüseyin Engin, Gokcen Tugba Çevik, Hüseyin Fatih Sezer
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Journal of Cardiothoracic Surgery
Subjects:
Online Access:https://doi.org/10.1186/s13019-024-03296-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585408828932096
author Aykut Eliçora
Berrak Güven
Hüseyin Engin
Gokcen Tugba Çevik
Hüseyin Fatih Sezer
author_facet Aykut Eliçora
Berrak Güven
Hüseyin Engin
Gokcen Tugba Çevik
Hüseyin Fatih Sezer
author_sort Aykut Eliçora
collection DOAJ
description Abstract Background Lung cancer is the leading cause of cancer-related deaths worldwide. Therefore, the search for new biomarkers continues in order to diagnose lung cancer at an early stage. In this study, we investigated blood levels of G-protein associated membrane estrogen receptor (GPER)-1 and Raftlin as markers of early-stage in lung cancer. Methods Lung cancer cases admitted to our hospital between 2016 and 2018 were included in our study. GPER-1 and Raftlin levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) in blood samples taken from patients diagnosed with lung cancer and healthy volunteers. Results There were 64 cases in total, 32 cases in lung cancer group and 32 cases in control group. We evluated GPER-1 levels for each group. GPER-1 level was 2.54 (IQR: 1.08–5.78) ng/mL in the lung cancer group and 5 (IQR: 2.69–7.99) ng/mL in the control group. ROC analysis value for GPER-1, (AUC) was 0.66 (p < 0.01). Raftlin levels were 4.5 (IQR: 3.3-11.52) ng/mL in control group and 7.77 (IQR: 6.24–9.85) ng/mL in lung cancer group. ROC analysis value for Raftlin, (AUC) was 0.629(P = 0.09). Conclusions In our study, there was no statistically significant difference between our groups in terms of Raftlin values. Therefore, it was thought that Raftlin could not be a specific marker in the diagnosis of lung cancer. GPER-1 was found to be lower in the lung cancer group than in healthy individuals. Therefore, it was thought that GPER-1 could be evaluated as a diagnostic marker in lung cancer. However, we think that more definitive results can be obtained by determining the tissue and expression level of GPER in lung cancer with further studies.
format Article
id doaj-art-2560a5e365594d68b491f4485cc7674b
institution Kabale University
issn 1749-8090
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series Journal of Cardiothoracic Surgery
spelling doaj-art-2560a5e365594d68b491f4485cc7674b2025-01-26T12:51:47ZengBMCJournal of Cardiothoracic Surgery1749-80902025-01-012011710.1186/s13019-024-03296-4Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer?Aykut Eliçora0Berrak Güven1Hüseyin Engin2Gokcen Tugba Çevik3Hüseyin Fatih Sezer4Kocaeli University Medical Faculty, Department of Thoracic SurgeryZonguldak Bülent Ecevit University Medical Faculty, Department of BiochemistryAcıbadem Bakırköy Hospital, Department of Medical Oncologyİstanbul Training and Research Hospital, Department of Medical OncologyKocaeli University Medical Faculty, Department of Thoracic SurgeryAbstract Background Lung cancer is the leading cause of cancer-related deaths worldwide. Therefore, the search for new biomarkers continues in order to diagnose lung cancer at an early stage. In this study, we investigated blood levels of G-protein associated membrane estrogen receptor (GPER)-1 and Raftlin as markers of early-stage in lung cancer. Methods Lung cancer cases admitted to our hospital between 2016 and 2018 were included in our study. GPER-1 and Raftlin levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) in blood samples taken from patients diagnosed with lung cancer and healthy volunteers. Results There were 64 cases in total, 32 cases in lung cancer group and 32 cases in control group. We evluated GPER-1 levels for each group. GPER-1 level was 2.54 (IQR: 1.08–5.78) ng/mL in the lung cancer group and 5 (IQR: 2.69–7.99) ng/mL in the control group. ROC analysis value for GPER-1, (AUC) was 0.66 (p < 0.01). Raftlin levels were 4.5 (IQR: 3.3-11.52) ng/mL in control group and 7.77 (IQR: 6.24–9.85) ng/mL in lung cancer group. ROC analysis value for Raftlin, (AUC) was 0.629(P = 0.09). Conclusions In our study, there was no statistically significant difference between our groups in terms of Raftlin values. Therefore, it was thought that Raftlin could not be a specific marker in the diagnosis of lung cancer. GPER-1 was found to be lower in the lung cancer group than in healthy individuals. Therefore, it was thought that GPER-1 could be evaluated as a diagnostic marker in lung cancer. However, we think that more definitive results can be obtained by determining the tissue and expression level of GPER in lung cancer with further studies.https://doi.org/10.1186/s13019-024-03296-4GPER-1RaftlinNon-small cell lung cancerSerum biomarkersNew tumor markers
spellingShingle Aykut Eliçora
Berrak Güven
Hüseyin Engin
Gokcen Tugba Çevik
Hüseyin Fatih Sezer
Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer?
Journal of Cardiothoracic Surgery
GPER-1
Raftlin
Non-small cell lung cancer
Serum biomarkers
New tumor markers
title Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer?
title_full Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer?
title_fullStr Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer?
title_full_unstemmed Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer?
title_short Could serum Raftlin and GPER-1levels be new biomarkers for early detection of non-small cell lung cancer?
title_sort could serum raftlin and gper 1levels be new biomarkers for early detection of non small cell lung cancer
topic GPER-1
Raftlin
Non-small cell lung cancer
Serum biomarkers
New tumor markers
url https://doi.org/10.1186/s13019-024-03296-4
work_keys_str_mv AT aykutelicora couldserumraftlinandgper1levelsbenewbiomarkersforearlydetectionofnonsmallcelllungcancer
AT berrakguven couldserumraftlinandgper1levelsbenewbiomarkersforearlydetectionofnonsmallcelllungcancer
AT huseyinengin couldserumraftlinandgper1levelsbenewbiomarkersforearlydetectionofnonsmallcelllungcancer
AT gokcentugbacevik couldserumraftlinandgper1levelsbenewbiomarkersforearlydetectionofnonsmallcelllungcancer
AT huseyinfatihsezer couldserumraftlinandgper1levelsbenewbiomarkersforearlydetectionofnonsmallcelllungcancer